A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Overview
- Phase
- Phase 3
- Intervention
- olaparib
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Sponsor
- AstraZeneca
- Enrollment
- 895
- Locations
- 133
- Primary Endpoint
- Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
- Status
- Active, not recruiting
- Last Updated
- 3 months ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
Detailed Description
PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio. Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the study protocol.
- •Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.
- •For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria:
- •Provision of informed consent for genetic research prior to collection of sample.
- •Provision of informed consent for biomarker research prior to collection of sample.
- •If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.
- •Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are \<20 years of age, written informed consent should be obtained from the patient and from his legally acceptable representative.
- •Histologically or cytologically confirmed prostate adenocarcinoma.
- •Metastatic status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan.
- •First-line metastatic castration-resistant prostate cancer (mCRPC).
Exclusion Criteria
- •Has a known additional malignancy that has had progression or has required active treatment in the last 5 years.
- •Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML).
- •Clinically significant cardiovascular disease Association Class II-IV heart failure or cardiac ejection fraction measurement of \<50% during screening as assessed by echocardiography or multigated acquisition scan.
- •Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure.
- •Prior revascularisation procedure (significant coronary, carotid, or peripheral artery stenosis).
- •Uncontrolled hypertension (systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or diastolic blood pressure (BP) ≥95 millimeters of mercury (mmHg)).
- •History of uncontrolled pituitary or adrenal dysfunction.
- •Active infection or other medical condition that would make prednisone/prednisolone use contraindicated.
- •Any chronic medical condition requiring a systemic dose of corticosteroid \>10 milligrams (mg) prednisone/prednisolone per day.
- •Patients who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
Arms & Interventions
olaparib plus abiraterone
Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.
Intervention: olaparib
olaparib plus abiraterone
Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.
Intervention: abiraterone acetate
placebo plus abiraterone
Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study. Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily.
Intervention: abiraterone acetate
Outcomes
Primary Outcomes
Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
Time Frame: Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.
Secondary Outcomes
- Number of Participants With Overall Survival (OS) Event(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made.)
- Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Number of Participants With Time to Pain Progression (TTPP) Event(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Number of Participants With Opiate Use(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Number of Participants With First Symptomatic Skeletal Related Event (SSRE)(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Number of Participants With Second Progression or Death (PFS2) Event(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Brief Pain Inventory-Short Form (BPI-SF)(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))
- Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)(Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months))